Evidence map›Paper›PMID 29313030›Full record

ArticleBioengineering & translational medicine2017

Poly(2-propylacrylic acid)/poly(lactic-co-glycolic acid) blend microparticles as a targeted antigen delivery system to direct either CD4

Lirong Yang, Evelyn Bracho-Sanchez, Lawrence P Fernando, Jamal S Lewis, Matthew R Carstens, Craig L Duvall, Benjamin G Keselowsky

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering & translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Lirong YangJ. Crayton Pruitt Family Dept. of Biomedical Engineering, College of Engineering University of Florida Gainesville, FL 32611.
Evelyn Bracho-SanchezJ. Crayton Pruitt Family Dept. of Biomedical Engineering, College of Engineering University of Florida Gainesville, FL 32611.
Lawrence P FernandoJ. Crayton Pruitt Family Dept. of Biomedical Engineering, College of Engineering University of Florida Gainesville, FL 32611.
Jamal S LewisJ. Crayton Pruitt Family Dept. of Biomedical Engineering, College of Engineering University of Florida Gainesville, FL 32611.
Matthew R CarstensJ. Crayton Pruitt Family Dept. of Biomedical Engineering, College of Engineering University of Florida Gainesville, FL 32611.
Craig L DuvallDept. of Biomedical Engineering Vanderbilt University Nashville, TN 37235.
Benjamin G KeselowskyJ. Crayton Pruitt Family Dept. of Biomedical Engineering, College of Engineering University of Florida Gainesville, FL 32611.ORCID 0000-0001-6474-7769
University of Florida · USVanderbilt University · US

Funding

MK2 Inhibitory Nanoplexes to Enhance Long-Term Vascular Graft PatencyR01HL122347 · NHLBI · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS · 2016 to 2020
$2.2M
Dendritic Cell-Targeting Microparticles for Subcellularly-Targeted Delivery of InR01DK091658 · NIDDK · UNIVERSITY OF FLORIDA · PI KESELOWSKY, BENJAMIN GEORGE · 2012 to 2016
$1.6M
Biomaterial Delivery System for Type 1 Diabetes VaccineR01DK098589 · NIDDK · UNIVERSITY OF FLORIDA · PI KESELOWSKY, BENJAMIN GEORGE · 2014 to 2017
$1.5M
Smart Polymer Based MK2 Inhibitor to Suppress Vascular Graft Intimal HyperplasiaR21HL110056 · NHLBI · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS · 2011 to 2012
$403k
High-Throughput Evaluation of Dendritic Cell-Targeting Vaccine Particles for theR21AI094360 · NIAID · UNIVERSITY OF FLORIDA · PI KESELOWSKY, BENJAMIN GEORGE · 2012 to 2013
$388k
NHLBI NIH HHS R01 HL122347NHLBI NIH HHS R21 HL110056NIAID NIH HHS R21 AI094360NIDDK NIH HHS R01 DK091658NIDDK NIH HHS R01 DK098589
6 · The paper itself

Abstract

Poly(lactic-co-glycolic acid) (PLGA) based microparticles (MPs) are widely investigated for their ability to load a range of molecules with high efficiency, including antigenic proteins, and release them in a controlled manner. Micron-sized PLGA MPs are readily phagocytosed by antigen presenting cells, and localized to endosomes. Due to low pH and digestive enzymes, encapsulated protein cargo is largely degraded and processed in endosomes for MHC-II loading and presentation to CD4

Indexed as

dendritic cellsendosomal escapeimmunotherapyintracellular deliverypH‐responsive polymerPLGApolymer blendPPAA

Identifiers

PMID29313030
PMCPMC5675098
OpenAlexW2710470270

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.